RGDXQ (Response Genetics) Total Liabilities: $15.87 Mil (As of Dec. 2015)


What is Response Genetics Total Liabilities?

Response Genetics RGDXQ -98.00% Total Liabilities is $15.87 Mil as of Dec. 2015.

Response Genetics's Total Liabilities for the quarter that ended in Dec. 2015 was $15.87 Mil.

Response Genetics's quarterly Total Liabilities increased from Dec. 2014 ($12.55 Mil) to Mar. 2015 ($15.72 Mil) and increased from Mar. 2015 ($15.72 Mil) to Dec. 2015 ($15.87 Mil).

Response Genetics's annual Total Liabilities increased from Dec. 2013 ($12.30 Mil) to Dec. 2014 ($12.55 Mil) and increased from Dec. 2014 ($12.55 Mil) to Dec. 2015 ($15.87 Mil).

Response Genetics Total Liabilities Historical Data

* Premium members only.

The historical data trend for Response Genetics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Response Genetics Total Liabilities Chart

Response Genetics Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.99 17.13 12.30 12.55 15.87

Response Genetics Quarterly Data
Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Dec15
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.21 14.26 12.55 15.72 15.87

Response Genetics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Response Genetics's Total Liabilities for the fiscal year that ended in Dec. 2015 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=9.865+(4.918+0.017000000000001
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0.752+0+0.315)
=15.87

Total Liabilities=Total Assets (A: Dec. 2015 )-Total Equity (A: Dec. 2015 )
=48.884-33.017
=15.87

Response Genetics's Total Liabilities for the quarter that ended in Dec. 2015 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=9.865+(4.918+0.017000000000001
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0.752+0+0.315)
=15.87

Total Liabilities=Total Assets (Q: Dec. 2015 )-Total Equity (Q: Dec. 2015 )
=48.884-33.017
=15.87

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $15.87 Mil mean?
Response Genetics (RGDXQ) has a Total Liabilities of $15.87 Mil as of Dec. 2015. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Response Genetics and its competitors.
Is Response Genetics' Total Liabilities too high?
Response Genetics' current Total Liabilities is $15.87 Mil.
How does Response Genetics' Total Liabilities compare to PSID and GBSN?
Response Genetics' Total Liabilities of $15.87 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Medical Diagnostics & Research company?
A good Total Liabilities depends on the Medical Diagnostics & Research industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Response Genetics and its competitors. Response Genetics's current Total Liabilities is $15.87 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Response Genetics stock overvalued right now?
Response Genetics (RGDXQ) has a current Total Liabilities of $15.87 Mil. The current Total Liabilities is $15.87 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Response Genetics (RGDXQ), the current Total Liabilities is $15.87 Mil as of Dec. 2015. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Response Genetics Business Description

Address 201 Route 17 North, 2nd Floor, Rutherford, NJ, USA, 07070
Response Genetics Inc develops and sells diagnostic tests. It provides molecular- and biomarker-based tests and services which enables physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment. The group generates revenue from providing Biopharma Services, Clinical Services, and Discovery Services, of which majority of the revenue is derived from providing Biopharma Services. Biopharma services provide companies with customized solutions for patient stratification and treatment selection through molecular- and biomarker-based testing services, customized assay development and trial design consultation. The firm operates in the US and internationally and generates prime revenue from the US.